Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Alternate-Day Fasting

ADF · Every-Other-Day Protocol

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

10 human trials, about 90 studies, ~2,000 participants across trials. The written rationale for this grade is still being prepared.

FDA
Not a regulated intervention
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

Strict alternate-day fasting carries high dropout in trials (around 38% over a year in the anchor study), intense fast-day hunger, and potential lean-mass loss without adequate protein and resistance training. One trial signal worth flagging: in Trepanowski 2017 the ADF group showed higher LDL cholesterol than the daily-restriction group at 12 months, so it is not uniformly cardioprotective. ADF is not appropriate during pregnancy or breastfeeding, for people on glucose-lowering or insulin medication, or for anyone with a history of disordered eating, where restrictive fast/feed cycling can be harmful. Anyone with a medical condition, on medication, pregnant, or with any history of an eating disorder should work with a qualified physician or registered dietitian before considering this pattern rather than self-directing it.

Alternate-day fasting alternates a fast day, commonly described as zero to roughly 500 calories, with a less-restricted feed day. It is one of the better-evidenced fasting patterns: Krista Varady's University of Illinois Chicago program plus Trepanowski 2017 (JAMA Internal Medicine) and Stekovic 2019 (Cell Metabolism) give it a real randomized-trial base, and 2025 meta-analyses pooling dozens of RCTs back meaningful short-to-medium-term weight and lipid effects. The recurring honest finding is equivalence, not superiority: head-to-head against ordinary daily calorie restriction, ADF produces similar weight loss with no clear cardiometabolic edge, and in the landmark trial it carried higher dropout. The unsolved problem is durability past a few months. ADF is associated with rapid early loss; sustaining it long-term is where most people fall off.

Fast every other day. Strong cardiovascular data, hard to sustain long-term.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Short-to-medium-term weight loss
  • Cardiovascular risk markers (blood pressure, inflammatory markers in some trials)
  • LDL and triglyceride reduction reported in obese-population trials
  • An alternative framing for people who find daily calorie counting harder to follow than periodic fast days
  • Visceral (abdominal) fat reduction comparable to daily calorie restriction

What people get wrong

  • Often saidADF lets you eat anything you want on feed days

    ActuallyVarady's own trials show most people do not fully compensate for fast-day calories, which is why the pattern works, but those who overeat on feed days erase the deficit. Feed-day behavior, not the fast itself, often decides the result (Varady program; Trepanowski 2017, JAMA Internal Medicine).

  • Often saidADF beats normal dieting for weight loss

    ActuallyAcross the strongest comparisons it is associated with roughly equivalent results, not superior ones. Trepanowski 2017 found no advantage over daily calorie restriction in weight loss, maintenance, or cardioprotection, and the 2025 BMJ network meta-analysis of 99 RCTs found ADF's edge over continuous restriction was 1.29 kg, below the threshold considered clinically meaningful.

  • Often saidADF is just unsustainable for everyone

    ActuallyStrict every-other-day fasting did show high attrition (38% dropout over 12 months in Trepanowski 2017). But the milder 4:3 variant in the 2025 Annals trial reported lower dropout than daily calorie restriction (19% vs 30%), so the sustainability problem tracks how aggressive the fast day is, not the alternating structure itself.

  • Often saidThe weight loss is mostly muscle

    ActuallyIn Trepanowski's body-composition analysis, fat-free mass was preserved and the lean-to-total-mass ratio improved similarly in ADF and daily calorie restriction. Lean-mass concern is real without protein and resistance training, but the data do not show ADF stripping muscle more than ordinary dieting does.

Who profits, and who pushes back

  • Dr. Krista Varady

    Promotes itUIC researcher

    The leading ADF researcher; her trials anchor the evidence base. Author of "The Every Other Day Diet."

  • Weight-loss community

    Promotes itMixed

    Used for rapid short-term loss; less common as a long-term lifestyle.

  • John Trepanowski and co-investigators

    Pushes backLead authors, JAMA Internal Medicine 12-month ADF vs daily calorie restriction RCT

    Alternate-day fasting did not produce superior adherence, weight loss, weight maintenance, or cardioprotection versus daily calorie restriction.

  • BMJ 2025 network meta-analysis authors

    Pushes backSynthesis of 99 randomized trials, 6,582 adults

    Among intermittent fasting strategies, alternate-day fasting was the only one to show benefit over continuous energy restriction for body weight, but the difference, about 1.29 kg, fell below what is considered clinically meaningful, at moderate certainty of evidence.

  • Sports-nutrition and muscle-physiology researchers

    Pushes backLean-mass and muscle-protein-remodeling perspective

    Intermittent fasting patterns are a suboptimal strategy for supporting muscle protein remodeling; aggressive alternating restriction without resistance training and protein targeting risks meaningful muscle loss.

Where the research comes from

Share of published research by country of origin.
PlaceShare of published research
USA48%
Europe30%
Other22%

Research published from: USA, Norway, Global.

How we got here

The idea predates the modern fasting wave by generations. The earliest systematic evidence came from Anton Carlson and Frederick Hoelzel, who reported in The Journal of Nutrition in 1946 that rats fasted one day in two, three, or four lived longer, with the one-in-three pattern extending lifespan most. Decades of rodent every-other-day feeding work followed in longevity research. Controlled human study arrived much later: Heilbronn and colleagues ran a proof-of-concept alternate-day fasting trial in nonobese adults in 2005, the source of several widely circulated metabolic claims. The intervention then moved into sustained clinical study largely through Krista Varady at the University of Illinois Chicago, whose group from the late 2000s systematically tested feed-day compensation, lipids, and cardiovascular markers. Trepanowski's 2017 head-to-head against daily calorie restriction and Stekovic's 2019 healthy-adult trial sharpened the picture, and 2025 network meta-analyses placed ADF firmly inside the broader intermittent-fasting evidence base.

  1. 1946Carlson and Hoelzel report intermittent fasting extends rat lifespan (J Nutrition), earliest systematic evidence
  2. 1990s-2000sEvery-other-day feeding studied extensively in rodent longevity research
  3. 2005Heilbronn et al. run proof-of-concept alternate-day fasting trial in nonobese adults (Am J Clin Nutr)
  4. late 2000s-2010sVarady program at University of Illinois Chicago runs a series of controlled ADF trials on weight, lipids, and cardiovascular markers
  5. 2017Trepanowski JAMA Internal Medicine trial: ADF not superior to daily calorie restriction, higher dropout (38% vs 29%)
  6. 2019Stekovic Cell Metabolism trial documents metabolic and cardiovascular changes in healthy non-obese adults
  7. 2025Annals 4:3 trial and BMJ 99-RCT network meta-analysis sharpen the equivalence-with-small-edge picture

At a glance

Pattern
Alternating fast/feed days
Fast-day intake
0-500 kcal
Evidence
Strong short-term
Sustainability
Low long-term

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Alternate-Day Fasting. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources